1. Home
  2. HCKT vs XNCR Comparison

HCKT vs XNCR Comparison

Compare HCKT & XNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HCKT
  • XNCR
  • Stock Information
  • Founded
  • HCKT 1991
  • XNCR 1997
  • Country
  • HCKT United States
  • XNCR United States
  • Employees
  • HCKT N/A
  • XNCR N/A
  • Industry
  • HCKT Professional Services
  • XNCR Biotechnology: Pharmaceutical Preparations
  • Sector
  • HCKT Consumer Discretionary
  • XNCR Health Care
  • Exchange
  • HCKT Nasdaq
  • XNCR Nasdaq
  • Market Cap
  • HCKT N/A
  • XNCR 625.6M
  • IPO Year
  • HCKT 1998
  • XNCR 2013
  • Fundamental
  • Price
  • HCKT $25.09
  • XNCR $7.68
  • Analyst Decision
  • HCKT Strong Buy
  • XNCR Buy
  • Analyst Count
  • HCKT 3
  • XNCR 9
  • Target Price
  • HCKT $31.33
  • XNCR $30.13
  • AVG Volume (30 Days)
  • HCKT 193.0K
  • XNCR 998.0K
  • Earning Date
  • HCKT 05-06-2025
  • XNCR 05-07-2025
  • Dividend Yield
  • HCKT 1.86%
  • XNCR N/A
  • EPS Growth
  • HCKT N/A
  • XNCR N/A
  • EPS
  • HCKT 0.84
  • XNCR N/A
  • Revenue
  • HCKT $307,532,000.00
  • XNCR $127,228,000.00
  • Revenue This Year
  • HCKT $6.06
  • XNCR N/A
  • Revenue Next Year
  • HCKT $5.46
  • XNCR $25.05
  • P/E Ratio
  • HCKT $30.73
  • XNCR N/A
  • Revenue Growth
  • HCKT 3.49
  • XNCR N/A
  • 52 Week Low
  • HCKT $20.23
  • XNCR $7.16
  • 52 Week High
  • HCKT $34.02
  • XNCR $27.24
  • Technical
  • Relative Strength Index (RSI)
  • HCKT 43.45
  • XNCR 36.63
  • Support Level
  • HCKT $25.52
  • XNCR $7.92
  • Resistance Level
  • HCKT $25.94
  • XNCR $8.26
  • Average True Range (ATR)
  • HCKT 0.82
  • XNCR 0.73
  • MACD
  • HCKT 0.12
  • XNCR -0.05
  • Stochastic Oscillator
  • HCKT 73.69
  • XNCR 3.38

About XNCR Xencor Inc.

Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.

Share on Social Networks: